Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
J Clin Invest. 2010 Feb;120(2):401-3. doi: 10.1172/JCI42088. Epub 2010 Jan 25.
The role of genetic heterogeneity within neoplasms is increasingly recognized as important for understanding the dynamics of cancer progression, cancer stem cells, and therapeutic resistance, and there is interest in intratumoral heterogeneity measurements as potential biomarkers for risk stratification. In this issue of the JCI, Park et al. characterize this genetic diversity in carcinoma in situ and in invasive regions from 3 types of human breast cancers and lay the groundwork for translation of these measures to the clinic.
肿瘤内遗传异质性的作用越来越被认为对于理解癌症进展、癌症干细胞和治疗抵抗的动态具有重要意义，并且人们对肿瘤内异质性测量作为风险分层的潜在生物标志物很感兴趣。在本期 JCI 中，Park 等人描述了 3 种人类乳腺癌的原位癌和浸润区域的这种遗传多样性，并为将这些测量方法转化为临床应用奠定了基础。
